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Purpose: Autosomal dominant progressive external ophthalmoplegia (adPEO) is a genetically heterogeneous, adult-onset
disease. Thus far, disease loci have been identified on four different nuclear genes. The purpose of this study is to identify
the gene responsible for causing adPEO in a Chinese family.
Methods: Clinical data and genomic DNA of a Chinese adPEO family were collected following informed consent. Gene
scan by two-point linkage analysis was performed for four genes, and mutation screening was conducted in the Twinkle
(PEO1) gene by direct sequencing.
Results: A maximum two-point LOD score of 2.8 at θ=0.00 was obtained with marker D10S192 in close proximity to
PEO1. A novel missense mutation (c.1423G>A, p.475A>T) was identified.
Conclusions: This study widens the mutation spectrum of PEO1 and is the first to report the PEO1 mutation in the Chinese
population.
Autosomal  dominant  progressive  external
ophthalmoplegia (adPEO, OMIM 157640) is an adult-onset
disease  with  typical  features  including  ptosis,  external
ophthalmoplegia,  and  slowly  progressive  skeletal  muscle
weakness. Some patients may also develop cardiomyopathy,
cataracts,  ataxia,  peripheral  neuropathy,  major  depression,
and  levodopa-responsive  Parkinsonism.  It  was  the  first
Mendelian  disorder  associated  with  multiple  deletions  of
mitochondrial DNA (mtDNA) [1-3]. At the same time, adPEO
is the most common genetically heterogeneous clinical entity
belonging to the subgroup of human mitochondrial disorders
caused by mutations in nuclear genes. Linkage analysis and
the screening of candidate genes in different sets of families
led to the discovery of pathogenic mutations in four different
nuclear genes: the muscle-brain and heart-specific isoform of
the adenine nucleotide translocator 1 (ANT1, on chromosome
4q), C10orf2 encoding a mitochondrial helicase (Twinkle,
also named PEO1, on chromosome 10q24), the sole mtDNA
polymerase  gene  (POLG,  on  chromosome  15q),  and
thymidine  phosphorylase  (TP,  on  chromosome  22q13.32)
[4-8]. The estimated frequencies of mutations in adPEO have
been  reported  to  be  4%–10%  for  ANT1,  15%–35%  for
PEO1, and 45% for POLG1. TP is mainly associated with
mitochondrial  neurogastrointestinal  encephalomyopathy
(MNGIE) [3-6,9-13]
Herein, we describe a Chinese adPEO family with a novel
mutation in PEO1.
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METHODS
Clinical evaluation and DNA specimens: A four-generation
adPEO  family  (Figure  1)  was  identified  through  the
Department of Neurology of the Second Affiliated Hospital
at the Zhejiang University College of Medicine in Hangzhou,
China. Informed consent in accordance with the Zhejiang
Institutional Review Board’s approved methods was obtained
from all participants. Twenty individuals participated in the
study, nine affected individuals and 11 unaffected individuals
(Figure  1).  All  these  family  members  were  investigated
according to their history of neurological examinations. A
general clinical examination, which included tests of the blood
lactate level, cranial magnetic resonance imaging (MRI), and
muscle biopsies, was performed only in the proband. Fundus
photographs were recorded by a TRC.50EX Retinal camera
(Topcon  Corp,  Tokyo,  Japan),  and  the  electroretinograms
were recorded on an LKC, UTAS-3000 (LKC Technologies
Inc.,  Gaithersburg,  MD).  Twenty  blood  specimens  were
collected  in  EDTA,  and  leukocyte  genomic  DNA  was
extracted by standard methods. DNA (n=100) was extracted
from  ethnically  matched,  apparently  healthy,  anonymous
adults (ranging in age from 18 to 65) composed of 42 females
and 58 males.
Muscle biopsy studies: Muscle biopsy of the biceps brachialis
was performed on the proband under local anesthesia. Tissues
were  prepared  for  light  and  electron  microscopic
examinations  (JEM-1230,  JEOL,  Tokyo,  Japan).  Frozen
sections  (10  mm  thick)  of  biceps  brachialis  muscle  were
stained  with  hematoxylin-eosin  (HE),  modified  Gomori’s
trichrome stain (GT), adenosine triphosphatase (ATPase; pH
9.4, 4.3, and 4.6), NADH-tetrazolium reductase, and succinate
dehydrogenase (SDH).Total DNA was extracted by standard
methods from the muscle biopsy of the proband.
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1995Genotyping  and  linkage  analysis:  The  same  group  of  20
family  members  was  genotyped  with  11  microsatellite
markers surrounding the locus of ANT1, PEO1, POLG1, and
TP [4-8]. Alleles were analyzed by GENESCAN Analysis
version 3.0 and GENOTYPER version 2.1 software (Perkin-
Elmer Applied Biosystems, Foster City, CA). Two-point LOD
scores  were  calculated  by  the  MLINK  program  of  the
LINKAGE package (version 5.1). The disease was specified
to  be  an  autosomal  chromosome  dominant  trait  with
penetrance  of  0.9  in  affected  individuals.  The  allele  and
recombination frequencies were assumed to be equal in males
and females. We assumed gene frequencies of 0.0001, and no
sex difference in recombination.
Direct sequencing and mutation analysis: A strong candidate
gene, PEO1, was polymerase chain reaction (PCR) amplified
using  the  primers,  Tw-Ex1–4  and  Tw-In1R,  as  published
previously [6]. Direct sequencing of the amplified fragments
was  performed  on  an  ABI  Prism  3130  Genetic  Analyzer
(Applied Biosystems, Foster City, CA). Sequencing results
were assembled and analyzed using the SeqMan II program
of the Lasergene package (DNA STAR Inc., Madison, WI).
For all samples containing an abnormal PEO1 amplicon, new
PCR products were re-amplified from genomic DNA using
the same protocols. Cosegregation analysis was performed.
Long-range polymerase chain reaction for mtDNA deletions:
Long-range PCR (TaKaRa LA Taq; Takara Bio Inc, Shiga,
Japan) for mtDNA deletions was performed as previously
described using a forward primer, nt 8285–8314, and a reverse
primer, nt 15574–15600, with an annealing temperature of
63.0 °C [13].
RESULTS
Clinical evaluation: The pedigree is shown in Figure 1. The
proband (III:13 in Figure 1) is a 44-year-old woman who had
bilateral progressive ptosis for eight years and had a three year
history of diplopia. Neurological examination revealed an
incomplete external ophthalmoplegia affecting all external
ocular muscles and bilateral ptosis (Figure 2). There was no
limb weakness or other abnormal neurological or psychiatric
features. A general clinical examination did not reveal any
abnormalities.  At  rest  and  during  moderate  exercise,  the
subject’s blood lactate levels were all normal. Serum creatine
kinase and electromyogram of the limb muscle were normal
as was the MRI of the brain. The fundus photographs and the
electroretinograms were also normal.
The proband’s 60-year-old aunt (II:9) has bilateral ptosis,
which  first  developed  in  her  early  30s,  and  external
ophthalmoplegia.  She  has  a  history  of  hypertension  and
lacunar infarction in the basal ganglia. At the age of 57, she
developed rigidity. However, she shows no resting tremor or
slurred  speech.  Additionally,  she  was  found  to  be
unresponsive  to  levodopa  and  diagnosed  with  Parkinson
syndrome.
The proband’s 68-year-old uncle (II:3) complained of
bilateral external ophthalmoplegia and ptosis at the age of 35.
Both of her brothers (III:15 and III:17) were unaware of any
clinical  abnormalities  in  themselves,  but  subsequent
Figure 2. Clinical photograph of the proband’s extraocular muscles.
Photograph of the proband show bilateral progressive ptosis and
external ophthalmoplegia affecting all external ocular muscles.
Figure 1. The pedigree of the Chinese family with adPEO. The index patient is indicated by an arrow. Family members who were sampled
for linkage analysis and mutation screening are indicated by an asterisk. Affected family members are shown as darkened symbols. The
mutation carriers who may be presymptomatic patients are indicated with dotted squares.
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1996examinations revealed mild ptosis and opthalmoparesis in
each. Neurological examinations of individuals IV:2 and IV:
3  revealed  no  symptoms.  Other  family  members  were
clinically examined and are shown in Table 1. None of the
affected  family  members  showed  limb  weakness  or  other
neurological or psychiatric abnormalities.
Muscle biopsies of the proband were analyzed. Gomori’s
modified trichrome stain showed scattered muscle fibers and
possible ragged red fibers (RRFs; magnification 40X; Figure
3A). SDH staining showed enhanced staining of the fiber
edges (Figure 3B). NADH stain showed normal type I fibers.
ATPase reaction showed the normal ratio of fiber type I and
II. HE staining revealed mild variability of fiber size without
necrosis (data not shown). Electron microscopic examination
showed  mitochondrial  proliferation  and  enlarged
mitochondria in a few muscle fibers but without crystalloid
inclusions (Figure 3C).
Linkage  analysis:  Candidate  loci  related  to  adPEO  were
initially  screened  with  11  markers.  Two-point  maximum
likelihood data for markers of this region is summarized in
Table 2. Two-point LOD scores were generated with markers
D10S192,  D10S597,  and  D10S185.  The  highest  observed
LOD score was 2.80 (θ=0.00) with marker D10S192. The
relation of the other genes (ANT1, TP, and POLG) to adPEO
was not supported by the genetic analysis, but significant
linkage was found with markers of the PEO1 locus in the
chromosome 10q23.3–24.3 region.
Mutation analysis: Through sequencing of PEO1, we found
a base change (c.1423G>A, p.A475T; Figure 4) at position
1423 of the PEO1 cDNA. This mutation has not been reported
previously and cosegregated with all affected members in this
Chinese family but was not detected in the 100 unrelated
normal  controls  or  in  the  unaffected  pedigree  members
(Figure 4).
mtDNA deletions analysis: The results of the long-range PCR
analysis are shown in Figure 5. The amplification of the 7.3
kb mtDNA fragment showed multiple deletions in the muscle
DNA samples taken from the proband, which were absent in
the normal control.
DISCUSSION
In this study, the highest LOD score of 2.80 was obtained at
marker  D10S192,  strongly  suggesting  this  adPEO  family
mapped to the locus on 10q24. This study also identified a
novel missense mutation in PEO1 (c.1423G>A, p.A475T).
The  pathogenicity  of  the  PEO1  mutation  is  based  on  the
following criteria: (1) it results in an amino acid exchange
Figure 4. DNA sequence chromatograms of PEO1 for unaffected and
affected members in the family. A single transition was observed at
position 1423 (G>A) of PEO1, causing a substitution of Ala to Thr
at codon 475 (A475T). A table of phylogenetic conservation is also
shown. Hs, Homo sapiens; MaMu, Macaca Mutallata; Mm, Mus
musculus; Cf, Canis familiaris; Eq, Equus Caballus; Xl, Xenopus
laevis, Dm, Drosophila melanogaster.
Figure 3. Light microscopic examination and electron microscopic examination of a 10 μm skeletal muscle transverse section. Gomori’s
trichrome stain showed possible red ragged fiber (RRF; A). Succinate dehydrogenase (SDH) staining showed enhanced staining of the fiber
edges (see arrows in B). Electron microscopic examination showed mitochondrial proliferation and enlarged mitochondria in a few muscle
fibers, there were no crystalloid inclusions (C).
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1997from the amino acid alanine to the amino acid threonine; (2)
the mutation harbors conserved residues, suggesting that this
residue is functionally significant to the protein; and (3) we
show that all living affected members of this family harbored
the  mutation  while  the  mutation  was  not  found  in  100
unrelated, healthy individuals, a result highly suggesting that
the c1423 G>A mutation segregates with the disease. The
p.A475T mutation identified in this study widens the mutation
spectrum of PEO1. Identification of the p.A475T missense
mutation  also  confirms  the  causative  role  of  the  PEO1
mutation. Interestingly, the p.A475P mutation has already
been  reported  in  adPEO  patients  of  different  ethnic
backgrounds [6,14] so it may be assumed that A475 is a
mutation hotspot. Variations in phenotypes are also seen in
other adPEO families affected by the p.A475P mutation. From
a clinical point of view, p.A475P mutations in PEO1 are
heterozygotes with dominant phenotypes. The patients may
have  a  negative  family  history  of  adPEO,  but  they  had
proximal muscle weakness, ataxia, neuropathy, depression or
avoidant personality traits, pes cavus, and tremors in addition
to progressive external ophthalmoplegia.
PEO is characterized by multiple mitochondrial DNA
deletions in the skeletal muscle. Both autosomal dominant and
autosomal recessive inheritance can occur with autosomal
recessive  mutations  of  PEO1  often  associated  with  more
severe symptoms such as early onset encephalopathy with
mtDNA  depletion  [3,9-11,13].  Twenty-one  different
mutations  have  been  identified  in  PEO1of  which  20  are
missense mutations. Mutations in PEO1 may be of variable
severity, being associated with clinical presentations ranging
from late-onset “pure” PEO to PEO complicated by proximal
limb and facial muscle weakness, dysphagia and dysphonia,
mild ataxia, and peripheral neuropathy. According to previous
research [6,9,10,12-19], mutations of PEO1 are present in
approximately 35% of familial PEO with multiple deletions
of  mtDNA.  Therefore,  PEO1  mutations  appear  to  be  a
common cause of family adPEO. No correlation has been
TABLE 1. CLINICAL INFORMATION ON THE FAMILY WITH ADPEO.
Individual Clinical feature
   Age/
onset age Neuroimage
PEO1
mutation
II: 1 Normal 72/- NP NO
II: 3 severe restriction of horizontal and
vertical eye movements
68/35 NP YES
II: 5 Normal 65/- NP NO
II: 8 Normal 63/- NP NO
II: 9 severe restriction of horizontal and
vertical eye movements, Parkinson
syndrome
60/30 lacunar infarction in
the basal ganglia
YES
II:10 Normal 60/- NP NO
III: 7 diplopia and severe restriction of
horizontal and vertical eye
movements
45/33 NP YES
III:13                                   Ptosis, severe restriction of
horizontal and vertical eye
movements
44/35 Normal YES
III: 14 Normal 44/- NP NO
III:15 Ptosis, mild restriction of horizontal
eye movements
36/32 NP YES
III:16 Normal 33/- NP NO
III: 17 Ptosis, mild restriction of horizontal
eye movements
34/32 NP YES
III:18 Normal 32/- NP NO
III:19 Ptosis, diplopia and mild restriction
of horizontal eye movements
30/30 NP YES
III:20 Normal 28/- NP NO
III:21 Ptosis, diplopia and mild restriction
of horizontal eye movements
33/30 NP YES
III:22 Ptosis, diplopia and mild restriction
of horizontal eye movements
31/30 NP YES
IV:1 Normal 17/- NP NO
IV:2 Normal 6/- NP YES
IV:3 Normal 4/- NP YES
This table describes the clinical information on affected and unaffected members in family members. “NP” stands for ” not
performed.”
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(proband)found between specific mutations and the severity of clinical
features [9-17].
In this family, the affected individuals with the A475T
substitution had a relatively mild clinical phenotype (mainly
represented by PEO), and the muscle biopsy exhibited fairly
subtle  changes  without  clear  signs  of  multi-systemic
involvement. Patient II:9 was unresponsive to levodopa and
diagnosed with Parkinson syndrome. This is different from
familial Parkinsonism because this patient’s syndrome was
due to a mutation in PEO1 [20]. Consideration of all of these
reported mutations in PEO1 might be important in deciding
which gene to investigate in other families presenting with
Figure 5. Long-range PCR for mtDNA deletion. Lane 1 shows the
muscle DNA of a normal control while lane 2 shows the muscle DNA
of  the  proband.  M  is  a  molecular  weight  marker.  The  multiple
mtDNA deletions in the proband can be observed, but not in the
normal control.
adPEO. In the proband, sensitive long-range PCR analysis
revealed multiple mtDNA deletions in the muscle samples,
but multiple mtDNA depletions were not shown in a normal
control, indicating a severely compromised PEO1 function in
the proband. MtDNA deletions are typical for the muscle of
adults with dominant PEO1 mutations and are thought to
accumulate by age, but there is not an obvious correlation
between mtDNA deletion load and clinical presentation [6,
13].
Normal human mitochondrial function involves a highly
complex interaction between the nuclear and mitochondrial
genomes. Hence, mutations in both mitochondrial and nuclear
encoded  genes  can  cause  mitochondrial  dysfunction  and
disease. PEO1, which is responsible for adPEO, encodes a
protein with homology to the T7 gene 4 protein (gp4) [6].
PEO1 is important for mtDNA maintenance, and its mutations
are  associated  with  progressive  external  ophthalmoplegia
with multiple mtDNA deletions [21,22]. Interestingly, many
mutations are clustered in a region of the Twinkle protein that
is probably involved in subunit interactions. In addition, the
A475 residue is located at the beginning of a very small helix
in the helicase domain and is in contact with the R374 present
in the linker region of the neighboring monomer. The A475
residue is conservative in terms of van der Waals interactions,
but a proline residue may induce a dramatic change in the
nature of the protein–protein interactions between the two
monomers  [21].  These  findings  suggest  that  the  A475T
mutation is a disease-causing change in PEO1.
In summary, our results reveal not only that a mutation
in PEO1 is associated with a Chinese adPEO family but also
that the mutation spectrum of PEO1 is expanded. This is the
first report of the PEO1 mutation in the Chinese population.
TABLE 2. LINKAGE RESULTS WITH MARKERS FROM THE GENES ANT1,PEO1, POLG1, AND TP.
Candidate
gene Markers LOD SCORES AT θ=
0 0.1 0.2 0.3 0.4 0.5
ANT1 D4s1535 −0.39 −0.3 −0.2 −0.09 −0.02 0
D4S426 −0.39 −0.31 −0.21 −0.1 −0.03 0
PEO1 D10S185 1.58 1.26 0.94 0.6 0.27 0
D10S192 2.8 2.27 1.68 1.03 0.39 0
D10S597 1.53 1.23 0.91 0.59 0.27 0
POLG1 D15S205 −0.6 −0.28 −0.12 −0.05 −0.01 0
D15S127 −4.58 −0.5 −0.21 −0.08 −0.02 0
D15S130 −0.26 −0.16 −0.09 −0.04 −0.01 0
TP D22S423 −0.26 −0.17 −0.1 −0.04 −0.01 0
D22S274 −4.25 −0.44 −0.18 −0.06 −0.01 0
Two-point LOD scores with markers from the genes ANT1 , PEO1 , POLG1 , and  TP are shown. The maximum two-point LOD
score (2.8) was achieved at D10S192 at θ=0.
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